Analysis 12.1.
Comparison 12 Losses to follow‐up, Outcome 1 Participants remaining at end of varenicline trials.
Participants remaining at end of varenicline trials
| Study | Placebo [%] | Varenicline [%] | Bupropion [%] | NRT [%] | Chi² and P value |
|---|---|---|---|---|---|
| Anthenelli 2013 | 179/269 (66.5%) | 175/256 (68.4) | 0.20, P = 0.66 | ||
| Aubin 2008 | 247/378 (65.3) | 230/379 (60.7) | 1.76, P = 0.18 | ||
| Baker 2016 | 389/424 (91.7) | Patch: 226/241 (93.8) C‐NRT: 408/421 (96.9) | 10.42, P = 0.005** | ||
| Bolliger 2011 | 156/199 (78.4) | 336/394 (85.3) | 4.44, P = 0.04* | ||
| Carson 2014 | 160/196 (81.6) | 165/196 (84.2) | 0.45, P = 0.50 | ||
| Chengappa 2014 | 20/29 (69.0) | 24/31 (77.4) | 0.55, P = 0.46 | ||
| Cinciripini 2013 | 76/106 (71.7) | 65/86 (75.6) | 73/102 (71.6) | 0.37, P = 0.54 | |
| De Dios 2012 | 7/11 (63.6) | 7/10 (70.0) | 9/11 (81.8) | 0.10, P = 0.76 | |
| EAGLES 2016 | 1552/2035 (76.3) | 1598/2037 (78.4) | 1586/2034 (80.0) | 1557/2038 (76.4) | 4.24, P = 0.24 |
| Ebbert 2015 | 516/750 (68.8) | 559/760 (73.6) | 4.16, P = 0.04* | ||
| Eisenberg 2016 | 112/151 (74.2) | 118/151 (78.1) | 0.66, P = 0.42 | ||
| Evins 2014 | 33/40 (82.5) | 26/47 (55.3) | 7.31, P = 0.007** | ||
| Gonzales 2006 | 187/344 (54.4) | 213/352 (60.5) | 184/329 (55.9) | 2.90, P = 0.23 | |
| Gonzales 2014 | 144/247 (58.8) | 169/251 (67.9) | 4.35, P = 0.04 | ||
| Hajek 2015 | 60/100 (60.0) | 66/100 (66.0) | 0.77, P = 0.38 | ||
| Heydari 2012 | 91/91 (100.0) | 89/89 (100.0) | 92/92 (100.0) | 0, P = 1 | |
| Jorenby 2006 | 204/341 (59.8) | 240/344 (69.8) | 221/342 (64.6) | 7.42, P = 0.02* | |
| Nahvi 2014a | 43/55 (78.2) | 49/57 (86.0) | 1.16, P = 0.28 | ||
| Nakamura 2007 | 132/154 (85.7) | 124/155 (79.5) | 1.78, P = 0.18 | ||
| NCT00828113 | 20/51 (39.2) | 20/50 (40.0) | 0.01, P = 0.94 | ||
| NCT01347112 | 12/16 (75.0) | 5/17 (29.4) | 10.24, P = 0.001** | ||
| Niaura 2008 | 89/160 (55.6) | 100/160 (62.5) | 1.56, P = 0.21 | ||
| Nides 2006 | 68/127 (53.5) | 77/127 (60.6) | 68/128 (53.1) | 1.83, P = 0.40 | |
| Oncken 2006 | 40/129 (31.0) | 146/253 (57.7) | 24.38, P < 0.001** | ||
| Rennard 2012 | 132/166 (79.5) | 432/493 (87.6) | 6.62, P = 0.01* | ||
| Rigotti 2010 | 289/359 (80.5) | 302/355 (85.1) | 2.61, P = 0.11 | ||
| Stein 2013 | 35/45 (77.8) | 115/137 (83.9) | 107/133 (80.5) | 1.05, P = 0.59 | |
| Steinberg 2011 | 21/39 (53.8) | 22/40 (55.0) | 0.01, P = 0.92 | ||
| Tashkin 2011 | 157/254 (61.8) | 176/250 (70.4) | 4.14, P = 0.04* | ||
| Tonstad 2006 | 463/607 (76.3) | 494/603 (81.9) | 5.83, P = 0.02* | ||
| Tsai 2007 | 117/124 (94.4) | 120/126 (95.2) | 0.10, P = 0.75 | ||
| Tsukahara 2010 | 14/16 (87.5) | 14/16 (87.5) | 0, P = 1 | ||
| Tønnesen 2013 | 54/69 (78.3) | 61/70 (87.1) | 1.92, P = 0.17 | ||
| Walker 2014 | 473/655 (72.2) [cytisine] | 482/655 (73.6) | 0.31, P = 0.58 | ||
| Wang 2009 | 161/168 (95.8) | 158/165 (95.8) | 0.001, P = 0.97 | ||
| Westergaard 2015 | 14/26 (53.8%) | 19/26 (73.1%) | 2.07, P = 0.15 | ||
| Williams 2007 | 59/126 (46.8) | 135/251 (53.8) | 1.63, P = 0.20 | ||
| Williams 2012 | 40/43 (93.0) | 75/85 (88.2) | 0.72, P = 0.40 | ||
| Wong 2012 | 119/135 (88.1) | 134/151 (88.7) | 0.02, P = 0.88 |